logo
Instead of worrying about your weight, focus on avoiding fragility

Instead of worrying about your weight, focus on avoiding fragility

CNN24-06-2025
Editor's note: Shift Your Mindset is an occasional series from CNN's Life, But Better team. We talk to experts about how to do things differently to live a better life.
Anti-aging aspirations have turned longevity products and services into a wellness-industry gold mine. But who wants to add on years only to spend them struggling to move, dependent on others and unable to enjoy basic activities?
What's the point of sticking around longer if you can't actually live life? Building and maintaining strength and mobility helps preserve the independence you need to age with dignity — and the actions you take now make all the difference.
In their new book 'The Complete Bone and Joint Health Plan: Help Prevent and Treat Osteoporosis and Arthritis,' dietitian and personal trainer Sydney Nitzkorski and orthopedic surgeon and sports medicine specialist Dr. Jocelyn Wittstein share the strategic diet and exercise choices you can make now to help maintain your quality of life well into your later years. Nitzkorski is a sports dietitian at Marist University in Poughkeepsie, New York, and she runs a private fitness and nutrition practice. Wittstein is an associate professor at Duke University School of Medicine in Durham, North Carolina.
This conversation has been edited and condensed for clarity.
CNN: What's the biggest misconception about bone and joint health?
Dr. Jocelyn Wittstein: Most people don't realize that bone mineral density (BMD) peaks at around age 30. After that, your goal is to maintain your BMD and try to slow down bone loss. For women, bone density decreases about 1% annually until menopause and then accelerates to 2% a year. Men experience a roughly 1% annual decline. The key is to build a strong foundation early and continue supporting your bone and joint health throughout your life.
Another misconception is that cardiovascular exercise alone is enough to preserve mobility, but strength training and light impact exercises are critical, too. These activities can elevate the peak bone density of people in their teens and 20s, while people older than 30 need those same exercises to minimize loss.
This is important considering that 1 in 4 adults will get osteoarthritis, and anyone older than age 50 has a heightened risk for both arthritis and osteoporosis, women in particular. A full 77% of postmenopausal women reported joint pain in a randomized study.
Sydney Nitzkorski: As a dietitian, I find that people don't think enough about how much calcium they're taking in, and most people are not getting enough. Your body can't make the calcium it needs, not just for bones and teeth but also heart, muscle and nerve function. If you're not consuming enough, your body will raid the reserves in your skeleton to meet its requirements.
This is why everybody, at every age, needs to get enough calcium. If you have kids, make sure they're consuming enough now, because this is when they're building bone mass. But sufficient calcium is still important even if you're 60 or beyond. Boosting your bone health is incredibly important at every age, and it's never too late to start taking proactive steps.
CNN: Are calcium supplements necessary?
Nitzkorski: Whole foods are the best sources for calcium, with supplementation as a secondary option. I recommend that people track their intake for a typical week and then adjust accordingly. Adults need 1,000 to 1,200 milligrams of calcium daily. Good sources include milk, fortified plant milks, broccoli and kale, as well as sardines and anchovies because you eat the bones.
Wittstein: Plus bok choy, which I consider a superfood. It's the green vegetable with the highest bioavailability of calcium. The calcium your body gets from a food depends on two factors: the total calcium the food contains and the bioavailability of that calcium, or how well the body absorbs and uses the mineral. A cup of milk has 300 milligrams of calcium that is 30% bioavailable, while a cup of bok choy has 160 milligrams that is 55% bioavailable. Yet, each one provides the body with an equivalent amount of calcium: about 87.5 milligrams. Along with bok choy's excellent calcium bioavailability, it also provides fiber and vitamins A and C. I love to prepare this green vegetable superfood with garlic, ginger and olive oil, making it an excellent anti-inflammatory food for joints and overall health.
CNN: Pressing question: Can we count the calcium from milk in coffee?
Nitzkorski: Yes! In the book, Jocelyn and I share that we both nail our calcium targets by drinking a lot of milk with a little bit of coffee. It's true that consuming more than 300 milligrams per day of caffeine lowers your body's calcium absorption — but that's a high bar when you consider an 8-ounce cup of coffee contains around 100 milligrams and a double shot of espresso contains about 140 milligrams.
Wittstein: Milk, whether it's from cows or a plant-based type that's been supplemented, is a good source of vitamin D, too. We know that consuming 2,000 IU of vitamin D a day can benefit bone health and may help decrease joint pain. When it comes to coffee, people are often glad to learn that it is rich in anti-inflammatory antioxidants. It contains the polyphenol quercetin, which may help alleviate pain and has anti-inflammatory properties.
I like to add cinnamon to my coffee for added anti-inflammatory effect and glucose control. You can also add whey protein — which provides amino acids that your body uses to build muscle — and/or collagen supplements, which can improve both bone density and joint pain, depending on the type.
CNN: What's the connection between inflammation and joint health?
Wittstein: Inflammation can break down cartilage and contribute to joint pain. Chronic inflammation accelerates joint deterioration. Anti-inflammatory nutrition taken in through diet and supplements like omega-3 fatty acids and curcumin, for example, can help ease symptoms like pain and swelling.
CNN: What does an anti-inflammatory diet look like?
Nitzkorski: What I love about recommending anti-inflammatory foods is that they provide so many other benefits, too, such as decreasing heart attack risk, increasing longevity, improving digestion and giving you more energy.
An anti-inflammatory diet is rich in lean proteins, which could be animal-based — such as non- or low-fat dairy, eggs, fish, chicken or turkey — or plant-based like beans, lentils and soy as well as pea proteins, which are found in a lot of protein powders. An anti-inflammatory diet also includes healthy fats, such as olive oil and foods containing omega-3 fatty acids like fish as well as walnuts and flax, chia and basil seeds.
Alliums — including garlic, onion, leeks and shallots — are flavorful plants that have multiple anti-inflammatory properties. And there's a whole spectrum of spices including turmeric, cayenne, black pepper and ginger.
Wittstein: Also important is dietary fiber from fruits, vegetables, beans and whole grains that provides short-chain fatty acids, higher levels of which are associated with lower levels of inflammation. Fruits and vegetables also contain myriad anti-inflammatory phytochemicals — naturally occurring compounds that provide an array of health benefits.
Avoiding or limiting inflammatory ingredients like processed meats, red meat, fried foods, saturated fats and processed carbohydrates is also important.
CNN: What types of exercise promote bone and joint health?
Wittstein: It's critical to incorporate resistance training and impact exercises. The goal is to work into your 150 minutes of weekly activity a combination of the following: three days of weight-bearing aerobic exercise, two days of resistance training, and two days of balance work and light-impact exercises.
That might sound like a lot, but these don't have to be long, intense sessions, and several of these types of conditioning can be combined. Standing on one leg and doing an overhead press counts as resistance training as well as balance work, for example. There are multiple things we want you to do to stimulate your bones and your muscles in different ways, but some of these activities can count as two.
Nitzkorski: You can also integrate little exercises into your daily life. Just as we lose muscle and bone mass with age, we also lose our ability to balance. Practice intentionally throwing yourself off balance a little bit so your body must work to find its equilibrium again.
Stand on one foot while brushing your teeth. Instead of sitting while watching TV, stand on one leg. Pretend a paintbrush is strapped to your toe and try to write your name or the alphabet. Write A through M on your right leg, and then switch and do N through Z on your left. To work on muscular endurance, do little arm circles. These start out super easy, but if you do them for two or three minutes it becomes exhausting.
CNN: What do you mean by light-impact exercises?
Wittstein: These include small jumps, jumping jacks or jumping rope. Studies show that doing 10 to 50 jumps three times a week is enough to stimulate your bone density. I encourage people to weave them into their day. By doing a little bit of hopping while you're waiting for the bus, you're getting your heart rate up and getting in some light-impact conditioning.
CNN: Do you recommend jumping if it causes knee pain?
Nitzkorski: No, people should listen to their joint pain! If jumping hurts your knees, focus on other kinds of conditioning like shallow squats, for example. You can also spread out your jumps over the course of the day or a week so you are not doing too many in a row. Or you can modify jumping exercises by using the back of a chair, or something else, for balance.
Wittstein: Or try modifications like pool jumping, which adds resistance and partly reduces impact. Water-based exercises are not as effective as land-based jumping exercises, but they are definitely beneficial for bone mineral density.
Although the gains from some of these exercise-based interventions may seem small, they actually translate to big risk reductions. We know from studies of pharmaceutical interventions that a 2% increase in lumbar-spine-bone density reduces spine fracture risk by 28%. A 4% improvement in hip-bone density decreases hip fracture risk by 32%. So even small improvements matter significantly.
CNN: Is it ever too late to start boosting your bone and joint health?
Nitzkorski: Absolutely not. While it's ideal to start early, you can always benefit from improving your diet and exercise routine. Start small — even 10 minutes of activity is better than nothing. Over time, small dietary changes can become a habit that sticks. The goal is consistency and gradual improvement so you can enjoy the life you live for that much longer.
Editor's note: Sign up for CNN's Fitness, But Better newsletter series. Our seven-part guide will help you ease into a healthy routine, backed by experts.
Jessica DuLong is a Brooklyn, New York-based journalist, book collaborator, writing coach and the author of 'Saved at the Seawall: Stories From the September 11 Boat Lift' and 'My River Chronicles: Rediscovering the Work That Built America.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Could EMR Alerts Boost Hypertension Detection?
Could EMR Alerts Boost Hypertension Detection?

Medscape

time24 minutes ago

  • Medscape

Could EMR Alerts Boost Hypertension Detection?

Could a simple advisory or alert in the electronic medical record (EMR) be the key to more frequent diagnosis and effective treatment of high blood pressure (BP)? While it could help, some physicians say it's not sufficient to solve the persistent problem of hypertension. However, such alerts could be part of an effective approach to catching more cases of hypertension and helping people manage their high BP. Tackling High BP Hypertension is well-known as a 'silent killer.' Left untreated, it raises the risk for heart attack, stroke, and other life-threatening events without causing any symptoms. Hypertension is also a widespread problem. The CDC estimates that about 120 million adults in the US have high BP, defined as having a systolic BP higher than 130 mm Hg or a diastolic BP greater than 80 mm Hg (or taking medication to lower their BP). However, only about 1 in 4 adults with high BP actually have their BP under control. According to the results of a recent quality improvement study in JAMA Network Open , using technology to prompt team-based care can improve primary care hypertension control and diagnosis in the ambulatory setting. The researchers tested an intervention consisting of a high BP advisory in the EMR, along with team training, audit, and feedback. If an elevated BP reading (systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg) was entered into the EMR, the medical assistant received an advisory to recheck the patient's BP. If the BP continued to be elevated, the EMR prompted a clinician-facing advisory, along with an order panel link. 'This study demonstrates that a paired human-technology intervention focused on team-based care and EMR integration is a fruitful approach to improving population health metrics,' the authors wrote. 'Anything that is done to alert the clinician is appropriate because of clinical inertia,' said Luke Laffin, MD, co-director of the Cleveland Clinic's Center for Blood Pressure Disorders in Cleveland, Ohio. 'There's a lot of clinical inertia in hypertension care. It breaks that inertia. I'm not surprised that this intervention works.' The Value of an Alert The idea of incorporating this type of alert into the EMR system is feasible, according to Brian Barr, MD, cardiologist at the University of Maryland Medical Center and assistant professor of medicine at the University of Maryland School of Medicine in Baltimore. 'Most modern EMRs — such as Epic, Cerner, Athenahealth, and others — are equipped with customizable clinical support tools that allow for automated reminders, alerts, and health maintenance prompts,' Barr said, adding that configurations could allow for notifications for missing BP readings or lack of documentation of BP within a particular time period. Alerts could also be quite useful to busy primary care physicians who see patients for a multitude of reasons. 'It's a reminder not to get distracted by the chief complaint syndrome,' said Brent Smith, MD, a family physician in Greenville, Mississippi and member of the board of directors for the American Academy of Family Physicians. 'It forces us not to overlook hypertension when there are other things that brought them into the doctor's office.' Using this type of tool could also identify patients with multiple elevated BP readings but no formal hypertension diagnosis, said Barr. That information could also allow physicians to follow patients more closely and confirm elevated BP in multiple settings — not just in the office, according to Blair Suter, MD, cardiologist with The Ohio State University Wexner Medical Center. 'It could be the canary in the coal mine,' he said. 'It could really be the sign of things to come or to progress to.' However, healthcare organizations must also be cautious about the possibility of contributing to electronic health record alert fatigue and instead find a balance that allows the use of technology to improve patient care without increasing the alert burden on clinicians. The authors of the study also acknowledged that some clinic managers had sustainability concerns about the time needed for BP rechecks. '[A]fter the rollout, some clinics piloted scheduling patients 10 minutes ahead of the clinician visit to increase previsit time for [medical assistants] to manage this and other population health initiatives,' they wrote. 'I think that rather than just having alerts, where people tend to get alarm fatigue, it might be more useful to focus on how we're collecting the data and how reliable it is and how much of a true reflection it is of the patient's true blood pressure when they're not in the office,' said Jeremy Bock, MD, interventional cardiologist and endovascular specialist at VHC Health in Arlington, Virginia. At-Home Monitoring Indeed, even if alerts do help, the challenge of getting patients to monitor their BP regularly at home does persist. At-home checks can seem nonurgent to them, especially if they are already taking an antihypertensive medication and feel fine. Kristen Trom, DO, family physician with Inspira Health in Mullica Hill, New Jersey, said that her organization's EMR uses an alert, but it's still a challenge to get patients to monitor their BP at home and take their medication. 'Resistance to starting medication can be a major challenge,' she said. 'Many of these patients have never been on medication before and prefer not to start.' 'It's trying to find that balance between being nonintrusive and also being part of their daily routine,' said Laffin. Physicians may need to spend more time emphasizing the importance of at-home BP monitoring and ensure patients know how to do it correctly. Prevention efforts can be time-consuming, noted Bock, but they can also improve patient-provider relationships and patient satisfaction. One important element of that process is reminding patients to use a validated BP cuff. Suter recommends directing patients to the website which is also suggested by the American Heart Association. Future Possibilities Time is often the biggest impediment for primary care providers. Eventually EMRs may be configured — along with AI — to incorporate the most effective cues and advisories, and then filter the information that would be most helpful for the physician, Smith said. 'It is getting better, and it has potential for the future,' he said. Barr added that other efforts could bolster such improvements. For example, clinic-level interventions also play a major role. 'Standardized blood pressure measurement protocols, routine use of home blood pressure monitoring, automated follow-up scheduling, and nurse-led hypertension visits can all support timely diagnosis and management,' Barr said. 'Engaging patients through portal alerts, educational messaging, and self-reported blood pressure entries adds another layer of protective care. Together, these strategies help close care gaps and support earlier identification and treatment of hypertension, ultimately improving long-term cardiovascular outcomes.'

Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Yahoo

time38 minutes ago

  • Yahoo

Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the next USD 39 million to Basilea to continue to advance the development of Basilea's novel antifungals fosmanogepix and BAL2062. This additional funding is based on the successful completion of a milestone within the 'Other Transaction Agreement' (OTA, agreement number 75A50124C00033) that was awarded on September 30, 2024, and which allows for potential funding of up to approximately USD 268 million in total to develop antifungal and antibacterial assets. David Veitch, Chief Executive Officer of Basilea, said: 'We are very pleased to receive the continued funding under the OTA with BARDA to support the development of our antifungal drug candidates fosmanogepix and BAL2062. Both compounds offer a novel mechanism of action and represent new therapeutic options for patients with aspergillosis, candidiasis or other life-threatening fungal infections. These infections primarily affect patients with weakened immune systems, such as cancer or transplant patients. Infections with difficult-to-treat rare molds or with resistance to current therapies are increasing. Hence, there continues to be a high medical need for new innovative antifungals.' He added: 'This second tranche of funding within the BARDA OTA will support the ongoing phase 3 study with fosmanogepix in yeast infections and the second phase 3 study, in mold infections, which is expected to start soon. It also provides funding for the preparation for the start of the phase 2 study for our antifungal BAL2062.' The USD 39 million is in addition to the initial USD 29 million BARDA committed at the signing of the OTA in September 2024. BARDA's financial contribution is about 60% of the total costs of the supported projects over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million, over up to 12 years, if all additional options to extend the contract are exercised by BARDA, upon successful completion of pre-defined milestones, including clinical and regulatory activities. About fosmanogepix Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order.1 Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections.1 A phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis is ongoing and the initiation of a second phase 3 study, in the treatment of adult patients with invasive mold infections, is expected soon.2 Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). About BAL2062 BAL2062 is a first-in-class antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains.3 Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses.4 The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis. About invasive mold infections Invasive aspergillosis and invasive infections with rare molds (e.g., Fusarium spp., Scedosporium spp., and Mucorales fungi) are life-threatening infections that predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with other immunodeficiency disorders. These infections are associated with high morbidity and mortality.5, 6 About invasive candidiasis Invasive candidiasis, including deep-seated tissue candidiasis and candidemia, is an increasingly important nosocomial infection, especially in patients hospitalized in intensive care units. Candida species are ranked as the fourth main cause of bloodstream infections in hospitals in the US.7 The prognosis of invasive candidiasis remains difficult, with a reported mortality rate for invasive candidiasis as high as 40%, even when patients receive antifungal therapy.8 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This project has been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The contract and federal funding are not an endorsement of the study results, product, or company. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This ad hoc announcement can be downloaded from References K. J. Shaw, A. S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi (Basel) 2020 (6), 239 FAST study (candidemia/invasive candidiasis): identifier NCT05421858; FORWARD study (invasive mold infections): identifier NCT06925321 K. J. Shaw. GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive Aspergillosis. Journal of Fungi (Basel) 2022 (8), 909 identifier NCT02956499: M. P. Mammen, D. Armas, F. H. Hughes et al. First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults. Antimicrobial Agents and Chemotherapy 2019 (63), e00969-19 J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434 M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10 Candidemia (Blood Infection) and Other Candida Infections. 2019 Factsheet by the American Thoracic Society: (Accessed: July 07, 2025) B. J. Kullberg, M. C. Arendrup. Invasive Candidiasis. The New England Journal of Medicine 2015 (373), 1445-1456 Attachment Press release (PDF)

Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Yahoo

timean hour ago

  • Yahoo

Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the next USD 39 million to Basilea to continue to advance the development of Basilea's novel antifungals fosmanogepix and BAL2062. This additional funding is based on the successful completion of a milestone within the 'Other Transaction Agreement' (OTA, agreement number 75A50124C00033) that was awarded on September 30, 2024, and which allows for potential funding of up to approximately USD 268 million in total to develop antifungal and antibacterial assets. David Veitch, Chief Executive Officer of Basilea, said: 'We are very pleased to receive the continued funding under the OTA with BARDA to support the development of our antifungal drug candidates fosmanogepix and BAL2062. Both compounds offer a novel mechanism of action and represent new therapeutic options for patients with aspergillosis, candidiasis or other life-threatening fungal infections. These infections primarily affect patients with weakened immune systems, such as cancer or transplant patients. Infections with difficult-to-treat rare molds or with resistance to current therapies are increasing. Hence, there continues to be a high medical need for new innovative antifungals.' He added: 'This second tranche of funding within the BARDA OTA will support the ongoing phase 3 study with fosmanogepix in yeast infections and the second phase 3 study, in mold infections, which is expected to start soon. It also provides funding for the preparation for the start of the phase 2 study for our antifungal BAL2062.' The USD 39 million is in addition to the initial USD 29 million BARDA committed at the signing of the OTA in September 2024. BARDA's financial contribution is about 60% of the total costs of the supported projects over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million, over up to 12 years, if all additional options to extend the contract are exercised by BARDA, upon successful completion of pre-defined milestones, including clinical and regulatory activities. About fosmanogepix Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order.1 Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections.1 A phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis is ongoing and the initiation of a second phase 3 study, in the treatment of adult patients with invasive mold infections, is expected soon.2 Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). About BAL2062 BAL2062 is a first-in-class antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains.3 Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses.4 The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis. About invasive mold infections Invasive aspergillosis and invasive infections with rare molds (e.g., Fusarium spp., Scedosporium spp., and Mucorales fungi) are life-threatening infections that predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with other immunodeficiency disorders. These infections are associated with high morbidity and mortality.5, 6 About invasive candidiasis Invasive candidiasis, including deep-seated tissue candidiasis and candidemia, is an increasingly important nosocomial infection, especially in patients hospitalized in intensive care units. Candida species are ranked as the fourth main cause of bloodstream infections in hospitals in the US.7 The prognosis of invasive candidiasis remains difficult, with a reported mortality rate for invasive candidiasis as high as 40%, even when patients receive antifungal therapy.8 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This project has been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The contract and federal funding are not an endorsement of the study results, product, or company. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This ad hoc announcement can be downloaded from References K. J. Shaw, A. S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi (Basel) 2020 (6), 239 FAST study (candidemia/invasive candidiasis): identifier NCT05421858; FORWARD study (invasive mold infections): identifier NCT06925321 K. J. Shaw. GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive Aspergillosis. Journal of Fungi (Basel) 2022 (8), 909 identifier NCT02956499: M. P. Mammen, D. Armas, F. H. Hughes et al. First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults. Antimicrobial Agents and Chemotherapy 2019 (63), e00969-19 J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434 M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10 Candidemia (Blood Infection) and Other Candida Infections. 2019 Factsheet by the American Thoracic Society: (Accessed: July 07, 2025) B. J. Kullberg, M. C. Arendrup. Invasive Candidiasis. The New England Journal of Medicine 2015 (373), 1445-1456 Attachment Press release (PDF)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store